<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36600518</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Establishment of the 1st Chinese national standard for CA6 neutralizing antibody.</ArticleTitle><Pagination><StartPage>2164140</StartPage><MedlinePgn>2164140</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2164140</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2022.2164140</ELocationID><Abstract><AbstractText>Coxsackievirus A6 (CA6) is one of the major causative agents of herpangina and hand-foot-mouth disease (HFMD). Since 2008, CA6 has circulated widely around the world. Especially in Asia-Pacific region CA6 had even replaced enterovirus A71 (EV71) and coxsackievirus A16 (CA16) as the main prevalent strain of HFMD. In the recent 10&#x2009;years, monovalent and multivalent vaccines against CA6 have been researched and developed by manufacturers from China, Korea, and the USA. The neutralizing antibody titer is a key indicator for accurately evaluating immunogenicity of vaccine. However, so far, the World Health Organization international standard for CA6 neutralizing antibody has not been available. In order to meet the needs of evaluating the immunogenicity of vaccines against CA6, the first Chinese national standard for CA6 neutralizing antibody was established, which was conducted to ensure that methods used to measure the neutralizing antibody titers against CA6 are accurate, reliable, and comparable. Three lyophilized candidate standards (29#, 39# and 44#) were produced with 0.40&#x2009;ml/vial from plasma samples donated by healthy individuals. The collaborative study showed that the 29# candidate standard could effectively minimize the variability in neutralization titers between labs and across challenging viruses of different genotypes (A, D1, and D3). Therefore, the 29# candidate sample was established as the first Chinese national standard for CA6 neutralizing antibody test. This standard has good long-term stability and was assigned a potency of 150 units per milliliter (U/ml) of CA6 neutralizing antibody. It will contribute to ensure uniformity of potency or activity of vaccines and potentially therapeutic antibody preparations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yiping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Huimin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junzhi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-1608-0389</Identifier><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus A6</Keyword><Keyword MajorTopicYN="N">collaborative study</Keyword><Keyword MajorTopicYN="N">hand-foot-mouth disease</Keyword><Keyword MajorTopicYN="N">national standard</Keyword><Keyword MajorTopicYN="N">neutralizing antibody</Keyword><Keyword MajorTopicYN="N">potency</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>5</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36600518</ArticleId><ArticleId IdType="pmc">PMC9980696</ArticleId><ArticleId IdType="doi">10.1080/21645515.2022.2164140</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hubiche T, Schuffenecker I, Boralevi F, L&#xe9;aut&#xe9;-Lab&#xe8;oze C, Bornebusch L, Chiaverini C, Phan A, Maruani A, Miquel J, Lafon M-E, et al. Dermatological spectrum of hand, foot and mouth disease from classical to generalized exanthema. Pediatr Infect Dis J. 2014;33(4):e92&#x2013;8. doi:10.1097/INF.0000000000000120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000120</ArticleId><ArticleId IdType="pubmed">24463804</ArticleId></ArticleIdList></Reference><Reference><Citation>Logotheti M, Pogka V, Horefti E, Papadakos K, Giannaki M, Pangalis A, Sgouras D, Mentis A.. Laboratory investigation and phylogenetic analysis of enteroviruses involved in an aseptic meningitis outbreak in Greece during the summer of 2007. J Clin Virol. 2009;46(3):270&#x2013;74. doi:10.1016/j.jcv.2009.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2009.07.019</ArticleId><ArticleId IdType="pubmed">19699142</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter J, Koptides D, Tryfonos C, Christodoulou C.. Molecular typing of enteroviruses associated with viral meningitis in Cyprus, 2000&#x2013;2002. J Med Microbiol. 2006;55(Pt 8):1035&#x2013;41. doi:10.1099/jmm.0.46447-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.46447-0</ArticleId><ArticleId IdType="pubmed">16849723</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh WM, Bogich T, Siegel K, Jin J, Chong EY, Tan CY, Chen MIC, Horby P, Cook AR. The epidemiology of hand, foot and mouth disease in Asia: a systematic review and analysis. Pediatr Infect Dis J. 2016;35(10):e285&#x2013;300. doi:10.1097/INF.0000000000001242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000001242</ArticleId><ArticleId IdType="pmc">PMC5130063</ArticleId><ArticleId IdType="pubmed">27273688</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Commission of the People&#x2019;s Republic of China . Diagnosis and treatment guideline on hand, foot and mouth disease (2018). Chin J Viral Dis. 2018;8(5):347&#x2013;52. doi:10.3760/cma.j.issn.1674-2397.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1674-2397.2018.03.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Cyril CYY, Susanna KP, Patrick CYW, Kwok-Yung Y. Human enterovirus 71 epidemics: what&#x2019;s next? Emerg Health Threats J. 2013;6(1):19780. doi:10.3402/ehtj.v6i0.19780.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/ehtj.v6i0.19780</ArticleId><ArticleId IdType="pmc">PMC3772321</ArticleId><ArticleId IdType="pubmed">24119538</ArticleId></ArticleIdList></Reference><Reference><Citation>LianLian B, YiPing W, Xin Y, Miao X, ZhengLun L, Liang Z. Coxsackievirus A6- a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide. Expert Rev Anti Infect Ther. 2015;13(9):1061&#x2013;71. doi:10.1586/14787210.2015.1058156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14787210.2015.1058156</ArticleId><ArticleId IdType="pubmed">26112307</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinlin L, Jing Y, Fan Y, ZhiQiang W, YongFeng H, Ying X, BoPing Z, Qi J. Epidemic characteristics of hand, foot, and mouth disease in southern China, 2013: coxsackievirus A6 has emerged as the predominant causative agent. J Infect. 2014;69(3):299&#x2013;303. doi:10.1016/j.jinf.2014.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2014.04.001</ArticleId><ArticleId IdType="pubmed">24731881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly F, Ilan Y, Huang J, McAdam A, Sandora TJ, Rennick M, Smole S, Rogers SL, Allan Nix W, Oberste MS, et al. Hand, foot, and mouth disease caused by coxsackievirus A6. Emerg Infect Dis. 2012;18(10):1702&#x2013;04. doi:10.3201/eid1810.120813.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1810.120813</ArticleId><ArticleId IdType="pmc">PMC3471644</ArticleId><ArticleId IdType="pubmed">23017893</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto T, Iizuka S, Enomoto M, Abe K, Yamashita K, Hanaoka N, Okabe N, Yoshida H, Yasui Y, Kobayashi M, et al. Hand, foot, and mouth disease caused by coxsackievirus A6, Japan, 2011. Emerg Infect Dis. 2012;18:(2):337&#x2013;39. doi:10.3201/eid1802.111147.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1802.111147</ArticleId><ArticleId IdType="pmc">PMC3310456</ArticleId><ArticleId IdType="pubmed">22304983</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomqvist S, Klemola P, Kaijalainen S, Paananen A, Simonen M, Vuorinen T, Roivainen M. Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virol. 2010;48(1):49&#x2013;54. doi:10.1016/j.jcv.2010.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2010.02.002</ArticleId><ArticleId IdType="pubmed">20189452</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrerizo M, Tarrag&#xf3; D, Mu1oz-Almagro C, Del Amo E, Dom&#xed;nguez-Gil M, Eiros JM, L&#xf3;pez-Miragaya I, P&#xe9;rez C, Reina J, Otero A, et al. Molecular epidemiology of enterovirus 71 coxsackievirus A16 and A6 associated with hand, foot and mouth disease in spain. Clin Microbiol Infect. 2014;20(3):150&#x2013;56. doi:10.1111/1469-0691.12361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12361</ArticleId><ArticleId IdType="pubmed">24033818</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) . Notes from the field: severe hand, foot, and mouth disease associated with coxsackievirus A6 &#x2013; Alabama, Connecticut, California, and Nevada, November 2011&#x2013;February 2012. MMWR Morb Mortal Wkly Rep. 2012;61(12):213&#x2013;14. http://archpsyc.jamanetwork.com/data/Journals/JAMA/24591/jwr120146_335_335.pdf?resultClick=1.</Citation><ArticleIdList><ArticleId IdType="pubmed">22456122</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair C, Gaunt E, Simmonds P, Broomfield D, Harvala H, Wellington L, Templeton K, Willocks L, Schofield O, Harvala H. A typical hand, foot, and mouth disease associated with coxsackievirus A6 infection, Edinburgh, United Kingdom, January to February 2014. Euro Surveill. 2014;19(12):20745. doi:10.2807/1560-7917.ES2014.19.12.20745.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES2014.19.12.20745</ArticleId><ArticleId IdType="pubmed">24698138</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirand A, le Sage FV, Pereira B, Cohen R, Levy C, Archimbaud C, Peigue-Lafeuille H, Bailly J, Henquell C. Ambulatory pediatric surveillance of hand, foot and mouth disease as signal of an outbreak of Coxsackievirus A6 infections, France, 2014&#x2013;2015. Emerg Infect Dis. 2016;22(11):1884&#x2013;93. doi:10.3201/eid2211.160590.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2211.160590</ArticleId><ArticleId IdType="pmc">PMC5088007</ArticleId><ArticleId IdType="pubmed">27767012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yeo A, Phoon MC, Yan W, Andrea Y, Phoon MC, Tan EL. The largest outbreak of hand, foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus a strains. Int J Infect Dis. 2010;14(12):e1076. doi:10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>YiJen C, ShihCheng C, KuoChien T, ShinRu S, ShuLi Y, TzouYi H, Huang Y-C. Comparative genomic analysis of coxsackievirus A6 strains of different clinical disease entities. PLoS One. 2012;7(12):e52432. doi:10.1371/journal.pone.0052432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052432</ArticleId><ArticleId IdType="pmc">PMC3530459</ArticleId><ArticleId IdType="pubmed">23300669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanbayashi D, Kaida A, Yamamoto SP, Hirai Y, Kubo H, Fujimori R, Hakui N, Hirokawa H, Iritani N. Impact of coxsackievirus A6 emergence on hand, foot, and mouth disease epidemic in Osaka city, Japan. J Med Virol. 2017;89(12):2116&#x2013;21. doi:10.1002/jmv.24905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24905</ArticleId><ArticleId IdType="pubmed">28771766</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiratchaya P, Thaweesak C, Piyada L, Sumeth K, Siwanat T, Preyaporn V, Apiradee T, Yong P. Hand, foot, and mouth disease caused by coxsackievirus A6, Thailand, 2012. Emerg Infect Dis. 2013;19(4):641&#x2013;43. doi:10.3201/eid1904.121666.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1904.121666</ArticleId><ArticleId IdType="pmc">PMC3647428</ArticleId><ArticleId IdType="pubmed">23631943</ArticleId></ArticleIdList></Reference><Reference><Citation>Biao D, Ying Z, Huaping X, Xiaoquan L, Chun C, Peng D, Peng H, Dahu W, Jinmei G, Lei L, et al. Circulation of Coxsackievirus A6 in hand-foot-mouth disease in Guangzhou, 2010-2012. Virol J. 2014;11(1):157. doi:10.1186/1743-422X-11-157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-11-157</ArticleId><ArticleId IdType="pmc">PMC4169826</ArticleId><ArticleId IdType="pubmed">25178398</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao K, Duan L, Peng Y, Wu M, Mai G, Yan Z, Chen S, Lu Y. Epidemiologic features of enterovirus associated with hand&#xff0c;foot and mouth disease in 2013 and 2014 in Shenzhen, China. Sci Rep. 2019;9(1):3856. doi:10.1038/s41598-019-40402-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-40402-2</ArticleId><ArticleId IdType="pmc">PMC6405776</ArticleId><ArticleId IdType="pubmed">30846756</ArticleId></ArticleIdList></Reference><Reference><Citation>Jie L, Ying S, Yiwei D, Yuxiang Y, Da H, Yuan L, Xiaoxia P, Yang Y, Fen L, Changying L, et al. Characterization of coxsackievirus A6- and enterovirus 71-associated hand foot and mouth disease in Beijing, China, from 2013 to 2015. Front Microbiol. 2016;7:391. doi:10.3389/fmicb.2016.00391.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2016.00391</ArticleId><ArticleId IdType="pmc">PMC4812011</ArticleId><ArticleId IdType="pubmed">27065963</ArticleId></ArticleIdList></Reference><Reference><Citation>Jie W, Jun Z, Guoliang X, Shufa Z, Yidong W, Chen Y, Wu Y. The epidemiological and clinical characteristics of hand, foot, and mouth disease in Hangzhou, China, 2016 to 2018. Clin Pediatr (Phila). 2020;59(7):656&#x2013;62. doi:10.1177/0009922820910822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0009922820910822</ArticleId><ArticleId IdType="pubmed">32146823</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhenjie Z, Zhaopen D, Qian W, Michael JC, Juan L, Tao L, Dong L, Weifeng S. Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine. 2018;36(46):7095&#x2013;104. doi:10.1016/j.vaccine.2018.09.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.069</ArticleId><ArticleId IdType="pubmed">30316529</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine EA, Fuchs J, Das SC, Partidos CD, Osorio JE. Efficacy of a trivalent hand, foot and mouth disease vaccine against enterovirus 71 and coxsackieviruses A16 and A6 in mice. Viruses. 2015;7(11):5919&#x2013;32. doi:10.3390/v7112916.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7112916</ArticleId><ArticleId IdType="pmc">PMC4664989</ArticleId><ArticleId IdType="pubmed">26593938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim H, In HJ, Lee JA, Sik Yoo J, Lee SW, Chung GT, Choi YK, Chung JK, Cho SJ, Lee JW. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine. 2018;36(24):3445&#x2013;52. doi:10.1016/j.vaccine.2018.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.05.005</ArticleId><ArticleId IdType="pubmed">29739716</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Wu SR, Lin HY, Yang YT, Liu WC, Chow YH, Shieh DB, Wang JR, Chong P. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antiviral Res. 2016;129:58&#x2013;66. doi:10.1016/j.antiviral.2016.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.02.008</ArticleId><ArticleId IdType="pubmed">26899790</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Shen C, Zhang C, Zhang W, Wang L, Lan K, Liu Q, Huang Z. Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective anti-bodies in mice. Antiviral Res. 2016;132:165&#x2013;69. doi:10.1016/j.antiviral.2016.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.06.004</ArticleId><ArticleId IdType="pubmed">27315772</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, Ku Z, Zhou Y, Li D, Wang L, Lan K, Liu Q, Huang Z. Virus-like particle-based vaccine against coxsackievirus A6 protects mice against lethal infections. Vaccine. 2016;34(34):4025&#x2013;31. doi:10.1016/j.vaccine.2016.06.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.06.028</ArticleId><ArticleId IdType="pubmed">27340093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai W, Zhang C, Zhou Y, Xiong P, Wang S, Ye X, Liu Q, Zhou D, Huang Z. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7(1):94. doi:10.1038/s41426-018-0094-l.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-l</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H, Yu S, Guo Y, Gu L, Wang G, Ren Z, Li Y, Li K, Li R. Development of a multivalent enterovirus subunit vaccine based on immunoinformatic design principles for the prevention of HFMD. Vaccine. 2020;38(20):3671&#x2013;81. doi:10.1016/j.vaccine.2020.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.03.023</ArticleId><ArticleId IdType="pubmed">32247566</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO CC . WHO collaborating center for standardization and evaluation of biologicals [accessed 2022 Oct
28]. https://www.nifdc.org.cn/nifdc/gjhz/whoshwhzzx/index.html.</Citation></Reference><Reference><Citation>WHO . WHO manual for the preparation of reference materials for use as secondary standards in antibody testing [M/OL]. In: WHO Expert Committee on Biological Standardization: Seventy-fifth report; 2022.  [accessed 2022 Oct
28]. https://www.who.int/publications/m/item/who-manual-for-reference-material-for-antibody-testing.</Citation></Reference><Reference><Citation>WHO . Recommendations for the preparation, characterization and establishment of international and other biological reference standards [M/OL]. In: WHO Expert Committee on Biological Standardization: fifty-fifth report; 2004.  [accessed 2022 Oct
28]. https://www.who.int/publications/i/item/9241209321.</Citation></Reference><Reference><Citation>Chinese Pharmacopoeia Commisson . Pharmacopeia of the People&#x2019;s Republic of China. Vol. III. Beijing: China Medical Science Press; 2020. p. 23&#x2013;24.</Citation></Reference><Reference><Citation>Tan D, Ma S. Yao pin jian du yu jian ding zhong de tong ji xue ying yong [Statistic applications in biopharmaceutical regulatory science]. Beijing: China Science and Technology Press; 2011. Chinese.</Citation></Reference><Reference><Citation>Mao Q, Wang Y, Bian L, Xu M, Liang Z. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect. 2016;5(7):e75. doi:10.1038/emi.2016.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2016.73</ArticleId><ArticleId IdType="pmc">PMC5141264</ArticleId><ArticleId IdType="pubmed">27436364</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F, Mao QY, Chen P, Bian LL, Yao X, Li JX, Zhu FC, Liang ZL. Seroepidemiology of Coxsackievirus A6,Coxsackievirus A16, and Enterovirus 71 infections in infants and children a prospective cohort study in Jiangsu, China. J Infect. 2016;73(5):509&#x2013;12. doi:10.1016/j.jinf.2016.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2016.08.008</ArticleId><ArticleId IdType="pubmed">27546063</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, Xu S, Zhang Y, Zhu SY, Wu DL, Yang XD, Liu H, Sun BX, Wu XY, Qin CF. Hand, foot, and mouth disease outbreak caused by coxsackievirus A6, China, 2013. J Infect. 2014;69(3):303&#x2013;05. doi:10.1016/j.jinf.2014.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2014.03.015</ArticleId><ArticleId IdType="pubmed">24704297</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Zeng H, Zheng H, Yi L, Guo X, Liu L, Sun L, Tan X, Li H, Ke C, et al. Hand, foot and mouth disease in Guangdong, China, in 2013: new trends in the continuing epidemic. Clin Microbiol Infect. 2014;20(7):O442&#x2013;45. doi:10.1111/1469-0691.12468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12468</ArticleId><ArticleId IdType="pubmed">24428125</ArticleId></ArticleIdList></Reference><Reference><Citation>Hongyan G, Chengjie M, Qiaozhi Y, Wenhao H, Juan L, Lin P, Yanli X, Hongshan W, Xingwang L. Hand, foot and mouth disease caused by coxsackievirus A6, Beijing, 2013. Pediatr Infect Dis J. 2014;33(12):1302&#x2013;03. doi:10.1097/INF.0000000000000467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000467</ArticleId><ArticleId IdType="pubmed">25037037</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JL, Yuan J, Yang F, Wu ZQ, Hu YF, Xue Y, Zhou BP, Jin Q. Epidemic characteristics of hand, foot, and mouth disease in southern China, 2013: coxsackievirus A6 has emerged as the predominant causative agent. J Infect. 2014;69(3):299&#x2013;303. doi:10.1016/j.jinf.2014.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2014.04.001</ArticleId><ArticleId IdType="pubmed">24731881</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Weng YW, He WX, Zhang YJ, Yang XH, Meng H, Xie JF, Wang JZ, Zheng KC, Yan YS. Molecular epidemiology of HFMD-associated pathogen coxsackievirus A6 in Fujian Province, 2011&#x2013;2013. Bing Du Xue Bao. 2014;30(6):624&#x2013;29. doi:10.13242/j.cnki.bingduxuebao.002575.</Citation><ArticleIdList><ArticleId IdType="doi">10.13242/j.cnki.bingduxuebao.002575</ArticleId><ArticleId IdType="pubmed">25868276</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Teng Z, Cui X, Li C, Pan H, Zheng Y, Mao S, Yang Y, Wu L, Guo X, et al. Epidemiological and serological surveillance of hand-foot-and-mouth disease in Shanghai, China, 2012&#x2013;2016. Emerg Microbes Infect. 2018;7(1):8. doi:10.1038/s41426-017-0011-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-017-0011-z</ArticleId><ArticleId IdType="pmc">PMC5837173</ArticleId><ArticleId IdType="pubmed">29362406</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu XF, Sun XM, Sun XW, Yang YQ, Huang CH, Wen H. Epidemiological study on hand, foot and mouth disease in Tongzhou District, Beijing, 2013&#x2013;2017. J Int Med Res. 2019;47(6):2615&#x2013;25. doi:10.1177/0300060519841974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060519841974</ArticleId><ArticleId IdType="pmc">PMC6567722</ArticleId><ArticleId IdType="pubmed">31099288</ArticleId></ArticleIdList></Reference><Reference><Citation>Si-Yuan LIU, Ya-Qian HUO, Mei-Rong GU, Fan GAO, Qun-Ying MAO, Wei JIANG, Lian-Lian BIAN. Molecular epidemic characteristics of pathogen of hand, foot and mouth disease in Guangdong and Jiangsu Provinces, China from 2018 to 2019. Chin J Biol. 2021;34(2):186&#x2013;91. doi:10.13200/j.cnki.cjb.003270.</Citation><ArticleIdList><ArticleId IdType="doi">10.13200/j.cnki.cjb.003270</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Report on the WHO collaborative study to establish the 1st International Standard for anti-EV71 serum (human), [EB/OL] [accessed 2022 Oct
28]. https://www.who.int/publications/m/item/WHO-BS-2015.2267.</Citation></Reference><Reference><Citation>World Health Organization . Report on the WHO collaborative study to establish the 1st International Standard for Enterovirus A71 inactivated vaccine, [EB/OL] [accessed 2022 Oct
28]. https://www.who.int/publications/m/item/WHO-BS-2019.2362.</Citation></Reference><Reference><Citation>Qunying M, YiPing W, Lianlian B, Fan G, Xin Y, Zhenglun L, Miao X, Junzhi W. R&amp;D and application of WHO international standards for enterovirus 71. Chin J Biol. 2016;29(12):1355&#x2013;57. doi:10.13200/j.cnki.cjb.001569.</Citation><ArticleIdList><ArticleId IdType="doi">10.13200/j.cnki.cjb.001569</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, Yao X, Li F, Yin W, Li Q, et al. Establishing China&#x2019;s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71(EV71) vaccines. Vaccine. 2011;29(52):9668&#x2013;74. doi:10.1016/j.vaccine.2011.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.10.018</ArticleId><ArticleId IdType="pubmed">22015395</ArticleId></ArticleIdList></Reference><Reference><Citation>Qunying M, Fan G, Lianlian B, Bopei C, Ruixiao D, Miao X, Zhenglun L. Assignment of international unit for national enterovirus 71 neutralizing antibody standard in China. Chin J Viral Dis. 2018;8(6):469&#x2013;75. doi:10.16505/j.2095-0136.2018.0099.</Citation><ArticleIdList><ArticleId IdType="doi">10.16505/j.2095-0136.2018.0099</ArticleId></ArticleIdList></Reference><Reference><Citation>Qunying M, Fan G, Zejun W, Xiuling L, Qiang G, Wenqi AN, Erxia Y, Lianlian B, Ruixiao D, Bopei C, et al. Collaborative study on calibration and applicability of national antigen standard for coxsackievirus A16 vaccine. Chin J Viral Dis. 2018;8(6):481&#x2013;86. doi:10.16505/j.2095-0136.2018.0107.</Citation><ArticleIdList><ArticleId IdType="doi">10.16505/j.2095-0136.2018.0107</ArticleId></ArticleIdList></Reference><Reference><Citation>Qunying M, Lianlian B, Fan G, Ce Y, Xin Y, Yiping W, Miao X, Zhenglun L. Collaborative calibration study of national potency reference for EV71 vaccine. Prog Microbiol Immunol. 2016;44(06):19&#x2013;22. doi:10.13309/j.cnki.pmi.2016.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.13309/j.cnki.pmi.2016.06.004</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>